153 articles with Centogene
With the Thanksgiving holiday fast-approaching in the United States, some investors are giving their thanks to five different pharma companies that became available on the stock exchange this month with an initial public offering.
Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies.
CENTOGENE Signs New Collaboration with PTC Therapeutics for Global Diagnostic Testing ProgramAromatic L-amino Acid Decarboxylase (AADC) Deficiency
Centogene N.V. announced that it has signed an agreement with PTC Therapeutics, Inc. for a global diagnostic program for aromatic L-amino acid decarboxylase deficiency.
CENTOGENE announced a new data access and collaboration agreement with Pfizer Inc.
Centogene B.V. announced the pricing of its initial public offering of 4,000,000 common shares at an initial public offering price of $14.00 per common share, for total gross proceeds of approximately $56 million.
Centogene has applied to list its common shares on the Nasdaq Global Market under the symbol “CNTG.”
Supporting rare disease diagnosis, education, and clinical research
CENTOGENE revealed the growth in its knowledge-base of rare hereditary diseases.
Driving personalized, immune-based therapy to target patients’ own immune responses
CENTOGENE biomarker measures lyso-Gb1 levels in children
Variant Prioritization Tool Driven by World’s Largest Curated Mutation Database
Research findings may provide deeper understanding on the role of genes that can contribute to development of Hypophosphatasia
In a whitepaper released, CENTOGENE provided an update on its induced pluripotent stem cells program.
CENTOGENE welcomed Germany’s Chancellor Dr. Angela Merkel to its headquarters together with Manuela Schwesig, Minister-President of Mecklenburg-Vorpommern.
One of the largest, most ethnically diverse studies of Parkinson’s disease to uncover the genetic basis of one of the most common neurodegenerative disorders
CENTOGENE announced the expansion of its executive leadership team with the appointment of Sun Kim in Boston, MA asChief Strategy & Investor Relations Officer.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman
CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.